KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Common Equity (2018 - 2025)

Castle Biosciences (CSTL) has disclosed Common Equity for 8 consecutive years, with $470.9 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 3.3% to $470.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $470.9 million through Dec 2025, up 3.3% year-over-year, with the annual reading at $470.9 million for FY2025, 3.3% up from the prior year.
  • Common Equity hit $470.9 million in Q4 2025 for Castle Biosciences, up from $467.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $470.9 million in Q4 2025 to a low of $378.8 million in Q2 2023.
  • Historically, Common Equity has averaged $419.3 million across 5 years, with a median of $413.8 million in 2021.
  • Biggest five-year swings in Common Equity: skyrocketed 376.05% in 2021 and later fell 10.17% in 2023.
  • Year by year, Common Equity stood at $411.7 million in 2021, then dropped by 3.06% to $399.2 million in 2022, then decreased by 1.97% to $391.3 million in 2023, then increased by 16.5% to $455.8 million in 2024, then grew by 3.3% to $470.9 million in 2025.
  • Business Quant data shows Common Equity for CSTL at $470.9 million in Q4 2025, $467.0 million in Q3 2025, and $455.4 million in Q2 2025.